Crescita Therapeutics (CTX) Q1 2025 earnings summary

Executive summary

• Q1-2025 revenue declined to $3,537K from $4,996K year-over-year, mainly due to timing of order fulfillment in Manufacturing.

• Net loss increased to $(932)K from $(626)K, reflecting lower sales and higher loss from operations.

• Adjusted EBITDA loss widened to $(679)K from $(325)K year-over-year.

• Management expects topline improvement in coming quarters as larger orders are delivered.

Financial highlights

• Gross profit was $1,747K, down from $2,411K year-over-year; gross margin improved to 49.4% from 48.3%.

• Operating expenses decreased to $2,809K from $3,142K, mainly due to lower headcount and partnership fees.

• Cash and cash equivalents at quarter-end were $8,538K, down $735K from prior year.

• Loss per share was $(0.05), compared to $(0.03) in Q1-2024.

Outlook and guidance

• Management anticipates revenue growth in subsequent quarters as delayed orders are fulfilled.

• Focus remains on disciplined capital deployment and balancing growth investments with financial strength.